These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Viridian Therapeutics ( NASDAQ:VRDN )
Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday. The company posted quarterly losses of $ ( 1.00 ) per share which beat the analyst consensus estimate of $ ( 1.02 ) per share.
Viridian ( VRDN ) Q2 Net Loss Widens 55%
Viridian Therapeutics ( NASDAQ:VRDN ) , a biotechnology company focused on therapies for autoimmune diseases including thyroid eye disease ( TED ) , released its second quarter 2025 results on August 6, 2025. The report highlighted major clinical progress with its lead TED candidate, veligrotug, ...
Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. ( VRDN ) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 8.42% and 55.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - Zevra Therapeutics ( NASDAQ:ZVRA )
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to Execute Strategic Plan
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team ...
Argenx ( ARGX ) Moves 4.4% Higher: Will This Strength Last?
Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Viridian Therapeutics, Inc. ( VRDN ) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 22.86% and 17.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Cabaletta Bio ( NASDAQ:CABA ) , C3.ai ( NYSE:AI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc analyst Eric Heath downgraded the rating for C3.ai, Inc.
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Aehr Test System ( NASDAQ:AEHR ) , Agios Pharmaceuticals ( NASDAQ:AGIO )
U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session after Wedbush maintained an Outperform rating on the stock and raised its price target from $400 to $515. Tesla shares gained 5% to $458.08 on ...
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Apogee Therapeutics ( NASDAQ:APGE ) , ARM Holdings ( NASDAQ:ARM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Exane BNP Paribas analyst Kevin Grundy initiated coverage on Constellation Brands, Inc.
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
SEATTLE, Nov. 21, 2024 ( GLOBE NEWSWIRE ) -- Umoja Biopharma, Inc. ( Umoja ) , the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR T-cells, today announced that Scott Myers has been appointed as Chairman of its Board of ...
Viridian Therapeutics, Inc. ( VRDN ) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -3.60% and 4.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MannKind ( MNKD ) Matches Q3 Earnings Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 9.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. ( STOK ) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 9.62% and 41.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints
The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday - Calavo Growers ( NASDAQ:CVGW )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Calavo Growers, Inc. CVGW rose sharply during Tuesday's session as the company posted stronger-than-expected results for its third quarter.
Why Is Viridian Therapeutics Stock Trading Higher On Tuesday? - Viridian Therapeutics ( NASDAQ:VRDN )
Tuesday, Viridian Therapeutics, Inc. VRDN released topline data from the THRIVE phase 3 clinical trial of VRDN-001 ( veligrotug ) , an intravenously delivered anti-insulin-like growth factor-1 receptor ( IGF-1R ) antibody, for active thyroid eye disease ( TED ) .
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Oracle ( NYSE:ORCL )
Shares of Oracle Corporation ORCL rose sharply in today's pre-market trading after the company reported better-than-expected earnings and sales results for its first quarter on Monday.
Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Lags Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -17.24% and 17.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Top 3 Health Care Stocks You May Want To Dump This Quarter - Verona Pharma ( NASDAQ:VRNA )
As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Strength Seen in Viridian Therapeutics ( VRDN ) : Can Its 8.7% Jump Turn into More Strength?
Viridian Therapeutics (VRDN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
What Could Biogen Buy? Three Surprise Names That Make Sense.
Biogen ( BIIB ) stock has mostly trended sideways this year, but that could soon change with $8 billion to $10 billion in acquisition-focused dry powder, an analyst said Tuesday. Wedbush analyst Laura Chico notes Biogen wrapped two high-profile acquisitions last year, taking over Reta ...
Viridian ( VRDN ) Up 10% on Clinical Updates for Eye Disease Drug
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in ...
Viridian Therapeutics, Inc. ( VRDN ) Reports Q1 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotech Sector a Healthy Choice for Investors? ( Nasdaq: ELTX ) ( Nasdaq: VRDN ) ( Nasdaq: KZIA ) ( Nasdaq: RGLS )
Biotech Sector a Healthy Choice for Investors? ...
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. ( VRDN ) and Encourages Investors to Contact the Firm
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. ( VRDN ... PR ...
How Much Upside is Left in Viridian Therapeutics, Inc. ( VRDN ) ? Wall Street Analysts Think 97.81%
The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Vir Biotechnology, Inc. ( VIR ) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 24.56% and 31.69%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. ( JANX ) Moves 5.6% Higher: Will This Strength Last?
Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why Viridian Therapeutics ( VRDN ) Stock Is Moving - Viridian Therapeutics ( NASDAQ:VRDN )
Viridian Therapeutics Inc VRDN shares are trading lower by 5.98% to $20.97 Thursday morning after the company announced pricing of an underwritten public offering, generating gross proceeds of approximately $150 million. The company is offering 7,142,858 shares of common stock at a public ...
BTIG Keeps Their Buy Rating on CymaBay Therapeutics ( CBAY )
BTIG Keeps Their Buy Rating on CymaBay Therapeutics (CBAY) - Markets Insider ...
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday - Cleveland-Cliffs ( NYSE:CLF ) , Cipher Mining ( NASDAQ:CIFR )
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday. Shares of ZimVie Inc. ZIMV shares rose sharply during Monday's session after the company disclosed an agreement to sell its spine business to H.I.G. Capital for $375 million.
Viridian Therapeutics, Inc. ( VRDN ) Reports Q3 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 10.66% and 74.38%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viridian Therapeutics, Inc. ( VRDN ) to Report a Decline in Earnings: What to Look Out for
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics, Inc. ( VRDN ) Stock Jumps 5.2%: Will It Continue to Soar?
Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday - BeiGene ( NASDAQ:BGNE ) , Alexander's ( NYSE:ALX )
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today's session. ImmunityBio, Inc. IBRX shares rose 19.4% to $2.9600. The FDA recently accepted ImmunityBio's resubmission of its Biologics License Application ...
Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock ( NYSE:BMY ) , SenesTech, Inc. - Common Stock ( NASDAQ:SNES )
On Wednesday, 311 stocks hit new 52-week lows. Bristol-Myers Squibb Company Common Stock BMY is the largest company in terms of market cap to set a new 52-week low this morning. SenesTech, Inc. - Common Stock SNES was the smallest company by market cap to set a new 52-week low. A10 Networks, ...
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday - Arhaus ( NASDAQ:ARHS ) , Decibel Therapeutics ( NASDAQ:DBTX )
Keybanc cut the price target for i3 Verticals, Inc. IIIV from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on Wednesday. Telsey Advisory Group increased Arhaus, Inc. ARHS price target from $13 to $15.
Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -0.79% and 78.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics ( SRPT ) Reports Q2 Loss, Misses Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 85.71% and 1.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Clearwater Analytics Announces Second Quarter 2023 Financial Results
Record Quarterly Revenue of $89.9 Million, Up 22% Year-Over-Year
Here's Why Viridian Therapeutics, Inc. ( VRDN ) is Poised for a Turnaround After Losing -20.23% in 4 Weeks
Viridian Therapeutics, Inc. (VRDN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2 Growth Stocks Wall Street Analysts Think Can Double in Value
Is now a good time to buy these promising healthcare stocks?
Why Shares of Viridian Therapeutics Are Falling Tuesday
The company announced preliminary trial results for its lead therapy.
Why This Biotech's Effort To Take On Horizon Fell Flat
VRDN Stock Collapses. Why This Horizon-Rivaling Update Fell Flat | Investor's Business Daily Investor's Business Daily ...
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
Broader markets seemed likely to start out on a positive note despite these two outliers.
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket - Better Therapeutics ( NASDAQ:BTTX ) , Acumen Pharmaceuticals ( NASDAQ:ABOS )
CytoMed Therapeutics Limited GDTC shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. Better Therapeutics, Inc.
Why Are Viridian Therapeutics Shares Falling Today - Viridian Therapeutics ( NASDAQ:VRDN )
Viridian Therapeutics Inc VRDN released preliminary data from its ongoing Phase 1/2 trial of VRDN-001 for chronic thyroid eye disease ( TED ) . Patients in the 10 mg/kg ( n=6 ) and 3 mg/kg ( n=6 ) cohorts treated with two doses of VRDN-001 were evaluated for changes in proptosis ( bulge ) , ...
Howard Marks says he's made five great market calls in his career. Here's how he did it.
Billionaire investor Howard Marks shared some investment wisdom with clients, including what he calls the "cardinal sin" of investing and how to avoid it.
